Bernstein keeps a bullish stance on HCA Healthcare, projecting modest EBITDA growth into 2026 and 2027

HCA Healthcare is attracting renewed attention from Wall Street after Bernstein reiterated a bullish view of the hospital operator, according to a Yahoo Finance report published Thursday.

The note emphasized valuation and forward performance. The coverage cited a forward price-to-earnings ratio of 12.27 for HCA and described the stock as having potential upside of 38.4%. It also characterized HCA as among the 10 lowest forward P/E stocks in the S&P 500, a framing that suggests the analyst sees the market price as relatively conservative versus expected earnings power.

Bernstein’s projections in the report focused on cash earnings before interest, taxes, depreciation and amortization, a common profitability measure for companies with heavy capital needs. The report said the firm expects EBITDA to grow 2.8% in 2026 and 4.6% in 2027, implying a gradual improvement rather than a sharp acceleration.

The hospital sector has been operating in a difficult macro backdrop, with uncertainty around staffing costs, labor negotiations, reimbursement trends, and utilization levels. The Yahoo Finance report referenced that environment as “cautious,” positioning Bernstein’s outlook as tempered but still positive. In that context, the analyst’s emphasis on low forward valuation and steady EBITDA growth reads as a bet that earnings resilience can offset near-term economic noise.

HCA’s business model centers on owning and operating hospitals, along with related services. Because the company runs a large network of facilities, investors typically watch for drivers like occupancy, mix of procedures, commercial and government payer dynamics, and the ability to manage labor and supply costs. While the Yahoo Finance item does not lay out these operating drivers in detail, the focus on forward EBITDA growth indicates Bernstein is looking beyond one-off factors and toward the trajectory of operating profitability.

In health care equities, forward P/E ratios are often used as a shorthand for expected earnings growth and risk. A forward P/E near 12 suggests the analyst believes consensus earnings estimates may already be discounted compared with peers or the broader index, which can be supportive if actual results track expectations. The report’s “top 10 lowest” characterization for forward P/E also implies Bernstein sees limited downside from valuation even if growth is moderate.

Still, the Yahoo Finance report does not provide additional breakdowns behind the 2.8% and 4.6% EBITDA growth assumptions, nor does it specify which components of earnings Bernstein expects to improve. It also does not disclose whether the firm adjusted estimates recently or what, if any, specific catalysts it is watching, such as reimbursement changes, new capacity additions, or contract terms.

For investors, the next question is whether HCA can keep translating operating conditions into steady EBITDA progress. Watch for the company’s subsequent quarterly results for signs that utilization and cost trends remain consistent with the forward view, and for any management commentary that clarifies how hospitals are managing labor, payor pressure, and margin discipline into 2026 and 2027. In the meantime, Bernstein’s note highlights a straightforward thesis: relatively low forward valuation paired with modest, steady earnings growth expectations. There is no guarantee the projections will hold, especially in a sector exposed to policy and cost swings.